IL299250A - Arimoclomol for the treatment of Gaucher disease - Google Patents

Arimoclomol for the treatment of Gaucher disease

Info

Publication number
IL299250A
IL299250A IL299250A IL29925022A IL299250A IL 299250 A IL299250 A IL 299250A IL 299250 A IL299250 A IL 299250A IL 29925022 A IL29925022 A IL 29925022A IL 299250 A IL299250 A IL 299250A
Authority
IL
Israel
Prior art keywords
arimoclomol
gaucher disease
treating gaucher
treating
disease
Prior art date
Application number
IL299250A
Other languages
English (en)
Hebrew (he)
Inventor
Thomas Kirkegaard Jensen
Anders M?rkeberg HINSBY
Cathrine Kolster FOG-T?NNESEN
Linda Ingemann
Dali Christine ?
Original Assignee
Kempharm Denmark As
Thomas Kirkegaard Jensen
Anders M?rkeberg HINSBY
Fog T?Nnesen Cathrine Kolster
Linda Ingemann
Dali Christine ?
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Denmark As, Thomas Kirkegaard Jensen, Anders M?rkeberg HINSBY, Fog T?Nnesen Cathrine Kolster, Linda Ingemann, Dali Christine ? filed Critical Kempharm Denmark As
Publication of IL299250A publication Critical patent/IL299250A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL299250A 2020-06-24 2021-06-24 Arimoclomol for the treatment of Gaucher disease IL299250A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
IL299250A true IL299250A (en) 2023-02-01

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299250A IL299250A (en) 2020-06-24 2021-06-24 Arimoclomol for the treatment of Gaucher disease

Country Status (14)

Country Link
US (1) US20230226036A1 (enExample)
EP (1) EP4171559B1 (enExample)
JP (2) JP2023531750A (enExample)
KR (1) KR20230035586A (enExample)
CN (1) CN116075305A (enExample)
AU (1) AU2021295437A1 (enExample)
BR (1) BR112022026396A2 (enExample)
CA (1) CA3183559A1 (enExample)
DK (1) DK4171559T3 (enExample)
ES (1) ES3056005T3 (enExample)
IL (1) IL299250A (enExample)
MX (1) MX2023000033A (enExample)
PT (1) PT4171559T (enExample)
WO (1) WO2021260120A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013125923A (ru) * 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
EP2484371B1 (en) * 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
NZ623910A (en) * 2009-07-28 2016-06-24 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
SI3448382T1 (sl) * 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
EP4171559A1 (en) 2023-05-03
US20230226036A1 (en) 2023-07-20
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
JP2023531750A (ja) 2023-07-25
DK4171559T3 (da) 2025-12-15
CN116075305A (zh) 2023-05-05
KR20230035586A (ko) 2023-03-14
EP4171559B1 (en) 2025-09-10
JP2026042936A (ja) 2026-03-11
ES3056005T3 (en) 2026-02-17
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
BR112022026396A2 (pt) 2023-03-14
JP7849574B2 (ja) 2026-04-21
AU2021295437A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
IL294594A (en) Methods of treating pemphigus
IL317293A (en) Online verification of medical devices
GB2605743B (en) Floor treatment machine
PT3448382T (pt) Arimoclomol para o tratamento de distúrbios associados à glucocerebrosidase
IL275091A (en) Methods for treating Gaucher's disease
GB202108224D0 (en) Treatment
CA196805S (en) Device for treating tissue
GB202103122D0 (en) Treatment
GB202003722D0 (en) Treatment
DK4171559T3 (da) Arimoclomol til behandling af Gauchers sygdom
GB202006236D0 (en) New treatment
GB202018400D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202104609D0 (en) New Treatments for Pain
GB202108302D0 (en) New treatment
GB202108300D0 (en) New treatment
GB202115604D0 (en) Floor treatment machine
IL273684A (en) Variants of beta-glucocerebrosidase for the treatment of Gaucher disease
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202016955D0 (en) Therapeutic treatments
GB202102488D0 (en) Treatment
GB202102373D0 (en) Treatment
GB202102410D0 (en) Treatment